Cargando…

Tissue factor as a new target for tumor therapy—killing two birds with one stone: a narrative review

BACKGROUND AND OBJECTIVE: Cancer is an important disease and can occur anywhere in the body. It is caused by uncontrolled cell growth that spreads to other body parts. This study extensively investigated the transmembrane receptor tissue factor (TF), which is the key motivator of the clotting cascad...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaoying, Cao, Dan, Zheng, Xiufeng, Wang, Gang, Liu, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761121/
https://www.ncbi.nlm.nih.gov/pubmed/36544632
http://dx.doi.org/10.21037/atm-22-5067
_version_ 1784852638583488512
author Li, Xiaoying
Cao, Dan
Zheng, Xiufeng
Wang, Gang
Liu, Ming
author_facet Li, Xiaoying
Cao, Dan
Zheng, Xiufeng
Wang, Gang
Liu, Ming
author_sort Li, Xiaoying
collection PubMed
description BACKGROUND AND OBJECTIVE: Cancer is an important disease and can occur anywhere in the body. It is caused by uncontrolled cell growth that spreads to other body parts. This study extensively investigated the transmembrane receptor tissue factor (TF), which is the key motivator of the clotting cascade and plays an essential role in cancer-associated coagulation. TF is considered to be aberrantly expressed in various tumors and appears to promote tumor angiogenesis and metastasis. Therefore, this study was performed to explain the pathological characteristics of TF expression and to discuss future cancer therapies that target TF. METHODS: We extensively reviewed the literature on TF published in PubMed, and discussed the effect of TF on tumor progression and TF-targeted therapeutics. KEY CONTENT AND FINDINGS: This review aimed to uncover how TFs contribute to tumor progression and cancer-associated thrombosis and summarize TF-based targeted therapy. Multiple functions and mechanisms of the TF in cancer-associated thrombosis and tumor progression were discussed. CONCLUSIONS: The current literature has confirmed that the TF is involved in the hypercoagulable state of tumors and promotes malignant tumors through coagulation-dependent or non-coagulation-dependent pathways. TF-dependent signaling is also involved in divergent cancer progression. Thus, TF-targeted therapeutics could have broad clinical applicability for the treatment of tumors.
format Online
Article
Text
id pubmed-9761121
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-97611212022-12-20 Tissue factor as a new target for tumor therapy—killing two birds with one stone: a narrative review Li, Xiaoying Cao, Dan Zheng, Xiufeng Wang, Gang Liu, Ming Ann Transl Med Review Article BACKGROUND AND OBJECTIVE: Cancer is an important disease and can occur anywhere in the body. It is caused by uncontrolled cell growth that spreads to other body parts. This study extensively investigated the transmembrane receptor tissue factor (TF), which is the key motivator of the clotting cascade and plays an essential role in cancer-associated coagulation. TF is considered to be aberrantly expressed in various tumors and appears to promote tumor angiogenesis and metastasis. Therefore, this study was performed to explain the pathological characteristics of TF expression and to discuss future cancer therapies that target TF. METHODS: We extensively reviewed the literature on TF published in PubMed, and discussed the effect of TF on tumor progression and TF-targeted therapeutics. KEY CONTENT AND FINDINGS: This review aimed to uncover how TFs contribute to tumor progression and cancer-associated thrombosis and summarize TF-based targeted therapy. Multiple functions and mechanisms of the TF in cancer-associated thrombosis and tumor progression were discussed. CONCLUSIONS: The current literature has confirmed that the TF is involved in the hypercoagulable state of tumors and promotes malignant tumors through coagulation-dependent or non-coagulation-dependent pathways. TF-dependent signaling is also involved in divergent cancer progression. Thus, TF-targeted therapeutics could have broad clinical applicability for the treatment of tumors. AME Publishing Company 2022-11 /pmc/articles/PMC9761121/ /pubmed/36544632 http://dx.doi.org/10.21037/atm-22-5067 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Article
Li, Xiaoying
Cao, Dan
Zheng, Xiufeng
Wang, Gang
Liu, Ming
Tissue factor as a new target for tumor therapy—killing two birds with one stone: a narrative review
title Tissue factor as a new target for tumor therapy—killing two birds with one stone: a narrative review
title_full Tissue factor as a new target for tumor therapy—killing two birds with one stone: a narrative review
title_fullStr Tissue factor as a new target for tumor therapy—killing two birds with one stone: a narrative review
title_full_unstemmed Tissue factor as a new target for tumor therapy—killing two birds with one stone: a narrative review
title_short Tissue factor as a new target for tumor therapy—killing two birds with one stone: a narrative review
title_sort tissue factor as a new target for tumor therapy—killing two birds with one stone: a narrative review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761121/
https://www.ncbi.nlm.nih.gov/pubmed/36544632
http://dx.doi.org/10.21037/atm-22-5067
work_keys_str_mv AT lixiaoying tissuefactorasanewtargetfortumortherapykillingtwobirdswithonestoneanarrativereview
AT caodan tissuefactorasanewtargetfortumortherapykillingtwobirdswithonestoneanarrativereview
AT zhengxiufeng tissuefactorasanewtargetfortumortherapykillingtwobirdswithonestoneanarrativereview
AT wanggang tissuefactorasanewtargetfortumortherapykillingtwobirdswithonestoneanarrativereview
AT liuming tissuefactorasanewtargetfortumortherapykillingtwobirdswithonestoneanarrativereview